Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.16 +10.1%	$2.59	$1.05 ▼ $4.13	$284.64M	1.89	596,760 shs	860,980 shs
FHTX Foghorn Therapeutics	$5.51 +12.7%	$4.48	$2.94 ▼ $10.25	$272.58M	3.05	142,448 shs	111,089 shs
PYXS Pyxis Oncology	$1.17 +3.5%	$1.19	$0.83 ▼ $5.39	$70M	1.13	732,856 shs	351,139 shs
RCKT Rocket Pharmaceuticals	$3.20 +8.1%	$4.24	$2.19 ▼ $26.98	$316.08M	0.67	2.23 million shs	4.34 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+10.49%	+12.06%	-11.48%	+180.89%	-0.32%
FHTX Foghorn Therapeutics	+12.68%	+11.31%	+20.04%	+70.59%	+12.91%
PYXS Pyxis Oncology	+3.54%	-2.50%	-13.33%	+28.95%	-58.66%
RCKT Rocket Pharmaceuticals	+8.11%	+11.11%	+5.96%	-35.22%	-84.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.5247 of 5 stars	3.5	2.0	0.0	0.0	0.8	0.6
FHTX Foghorn Therapeutics	1.2916 of 5 stars	3.6	0.0	0.0	0.0	1.7	0.6
PYXS Pyxis Oncology	1.6695 of 5 stars	3.4	1.0	0.0	1.8	0.8	0.6
RCKT Rocket Pharmaceuticals	4.8465 of 5 stars	4.2	2.0	4.7	1.7	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	145.25% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	120.05% Upside
PYXS Pyxis Oncology	2.80	Moderate Buy	$9.00	669.23% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	481.25% Upside

Current Analyst Ratings Breakdown

Latest PYXS, RCKT, FHTX, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.42	N/A	N/A	($2.10) per share	-1.50
FHTX Foghorn Therapeutics	$22.60M	13.59	N/A	N/A	($0.82) per share	-6.72
PYXS Pyxis Oncology	$16.15M	4.49	N/A	N/A	$2.03 per share	0.58
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
PYXS Pyxis Oncology	-$77.33M	-$1.59	N/A	N/A	N/A	N/A	-57.49%	-45.17%	8/13/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest PYXS, RCKT, FHTX, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
5/15/2025	Q1 2025	PYXS Pyxis Oncology	-$0.29	-$0.35	-$0.06	-$0.35	N/A	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
FHTX Foghorn Therapeutics	N/A	3.16	3.16
PYXS Pyxis Oncology	N/A	7.75	7.75
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
FHTX Foghorn Therapeutics	61.55%
PYXS Pyxis Oncology	39.09%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
FHTX Foghorn Therapeutics	7.58%
PYXS Pyxis Oncology	10.60%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
PYXS Pyxis Oncology	60	61.95 million	55.38 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

PYXS, RCKT, FHTX, and ADCT Headlines

Recent News About These Companies

NUST Rocket Team Wins “Most Dedicated Team” at UK’s Mach-25 Competition

3 hours ago | techjuice.pkT

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT - Stockhouse

July 9 at 10:09 PM | stockhouse.com

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

July 9 at 5:16 PM | prnewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

July 9 at 5:11 PM | globenewswire.com

Rocket Announce Debut Album, Hear: “Wide Awake”

July 9 at 5:08 PM | pastemagazine.comP

Rocket CRM Announces Advanced CRM Automation System to Streamline Customer Management and Operational Efficiency

July 9 at 5:08 PM | freep.comF

2025-07-07 | Rocket Pharmaceuticals, Inc. (RCKT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse

July 8 at 8:33 PM | stockhouse.com

Rocket Pharmaceuticals, Inc. (RCKT) - Yahoo Finance

July 8 at 8:33 PM | finance.yahoo.com

Levi & Korsinsky Notifies Shareholders of Rocket Pharmaceuticals, Inc.(RCKT) of a Class Action Lawsuit and an Upcoming Deadline

July 8 at 3:49 PM | globenewswire.com

India Bolsters Naval Might with Extended Range Anti-Submarine Rocket Success

July 8 at 3:31 PM | devdiscourse.comD

India Boosts Naval Strength with Indigenous Anti-Submarine Rocket Success

July 8 at 3:31 PM | devdiscourse.comD

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 8 at 12:00 PM | prnewswire.com

RCKT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RCKT To Contact Him Directly To Discuss Their Options

July 8 at 11:20 AM | prnewswire.com

Robbins Geller Rudman & Dowd LLP Files Rocket Pharmaceuticals Class Action Lawsuit

July 8 at 10:31 AM | lawyer-monthly.comL

August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT

July 8 at 9:00 AM | prnewswire.com

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCKT

July 8 at 6:00 AM | globenewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Share Price Passes Below 50 Day Moving Average - Should You Sell?

July 8 at 4:56 AM | marketbeat.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 7 at 9:10 PM | prnewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action â€“ RCKT

July 7 at 7:03 PM | globenewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKT

July 7 at 4:47 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

July 7 at 2:45 PM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, RCKT, FHTX, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.16 +0.29 (+10.10%)

Closing price 07/9/2025 03:57 PM Eastern

Extended Trading

$3.17 +0.01 (+0.19%)

As of 04:01 AM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Foghorn Therapeutics NASDAQ:FHTX

$5.51 +0.62 (+12.68%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$5.50 0.00 (-0.09%)

As of 04:06 AM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology NASDAQ:PYXS

$1.17 +0.04 (+3.54%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$1.16 -0.01 (-0.85%)

As of 07/9/2025 07:19 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.20 +0.24 (+8.11%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$3.21 +0.01 (+0.31%)

As of 04:50 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time